Structured Abstract (nejm-abstract)

When to trigger

• Significance, design, reporting, and statistics are settled (do this late).
• The abstract is unstructured prose, or exceeds the word cap.
• The Results section reports P values but not the primary outcome with its effect size and CI.
• The trial registration number and funding source are missing.

The four required sections (Background, Methods, Results, Conclusions)

NEJM uses a structured abstract, ≤250 words, with four headed sections. Confirm the exact cap against the current author guidelines; design for 250 as the ceiling.

Background

One or two sentences: the clinical problem and the specific question. State why the question matters in practice — no extended literature review.

Methods

Design (e.g., "randomized, double-blind, placebo-controlled trial"), population and setting, intervention/comparator, randomization, the pre-specified primary outcome and key secondary outcomes, and the analysis population (intention-to-treat).

Results

Lead with the primary outcome. Report the effect size with a 95% confidence interval — absolute difference and/or relative measure (hazard ratio, risk ratio, odds ratio) — plus the P value if used. Give the number analyzed per group. Report key secondary outcomes and serious adverse events. Numbers, not adjectives.

Conclusions

One or two sentences answering the question, calibrated to the evidence. Name the comparator. End with the trial registration number and the funding source.

Hard constraints

• ≤ ~250 words across the four sections (confirm against current guidelines).
• Four headed sections present: Background / Methods / Results / Conclusions.
• Primary outcome reported with effect estimate + 95% CI (not P alone).
• Analysis population (ITT) and per-group n stated.
• Trial registration number included (e.g., "ClinicalTrials.gov number, NCT00000000").
• Funding source stated (e.g., "Funded by …").
• No undefined acronyms; no citations; no figure/table references.

Concrete template (RCT)

BACKGROUND
[Clinical problem]. It is unknown whether [intervention] improves [patient-important
outcome] in [population].

METHODS
We conducted a [design, e.g., multicenter, randomized, double-blind, placebo-controlled]
trial. We randomly assigned [N] patients with [condition] to [intervention] or
[comparator]. The primary outcome was [outcome] at [time]. Analyses were performed
according to the intention-to-treat principle.

RESULTS
The primary outcome occurred in X of N patients ([x.x]%) in the [intervention] group and
in Y of N ([y.y]%) in the [comparator] group (absolute difference, [z.z] percentage points;
95% CI, [a] to [b]; hazard ratio, [h]; 95% CI, [c] to [d]; P=[p]). [Key secondary outcome].
[Serious adverse events by group].

CONCLUSIONS
Among patients with [condition], [intervention] [did/did not] [effect on outcome] as
compared with [comparator]. (Funded by [funder]; [TrialName] ClinicalTrials.gov number,
NCT00000000.)

Operating pass for New England Journal of Medicine

Use this as a second-pass capability check. First lock the clinical question, population, endpoint, effect size, safety signal, and practice implication; then test whether the manuscript addresses clinical-medicine reviewers who expect practice-changing evidence, patient relevance, safety, and exact reporting discipline.

• Primary move: Return a claim-evidence-risk ledger; every recommendation must point to a manuscript location or missing artifact.
• Decision ledger: return claim / evidence / blocker / next edit rows so the next pass can patch the manuscript directly.
• Neighbor test: compare against JAMA for broad clinical medicine, Lancet for global-health/public-health reach, specialty journals for narrower disease domains; if the neighboring outlet has the stronger audience claim, recommend re-routing before polishing.
• Verification floor: before submission-ready advice, re-open resources/official-source-map.md for volatile rules and name the one unresolved fact that could change the recommendation.

Output format

【Word count】 N ≤ 250
【Four sections present】 Background / Methods / Results / Conclusions — yes/no
【Primary outcome with effect + 95% CI】 yes/no + the numbers
【ITT + per-group n stated】 yes/no
【Registration number present】 yes/no (NCT…)
【Funding source present】 yes/no
【Acronym / citation hits removed】 [...]
【Next】 nejm-citation

Anti-patterns

• Do not write an unstructured single-paragraph abstract — NEJM uses the four headed sections.
• Do not report only a P value for the primary outcome — give the effect estimate and 95% CI.
• Do not lead the Results with a secondary or subgroup finding.
• Do not omit the registration number or funding source — both belong in the Conclusions sentence.
• Do not state conclusions that outrun the data (over-claiming is a top rejection reason).